Publication date: Jul 08, 2025
Patients on ambroxol dropped an average of 2. 45 points. Related: Parkinson’s Disease Might Not Start in The Brain, Study FindsBoth groups shared similar cognitive scores related to memory and language. “These findings suggest ambroxol may protect brain function, especially in those genetically at risk,” says Pasternak. “In the team’s analysis, some participants carrying a high-risk GBA1 gene for Parkinson’s showed improved cognitive performance on ambroxol. If a drug like Ambroxol can help, it could offer real hope and improve lives. But the recent phase 2 trial on Parkinson’s dementia gives scientists good reason to keep digging. “This early trial offers hope and provides a strong foundation for larger studies. “Our goal was to change the course of Parkinson’s dementia,” says neurologist Stephen Pasternak from Western University in Canada.
| Concepts | Keywords |
|---|---|
| Australia | Activity |
| Canada | Ambroxol |
| Daily | Brain |
| Dementia | Cough |
| Glucocerebrosidase | Dementia |
| Drug | |
| Found | |
| High | |
| Neuropsychiatric | |
| Parkinson | |
| Participants | |
| Related | |
| Showed | |
| Symptoms | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s disease |
| disease | MESH | dementia |
| drug | DRUGBANK | Ambroxol |
| drug | DRUGBANK | Gold |
| disease | MESH | delusions |
| disease | MESH | hallucinations |
| disease | MESH | anxiety |
| disease | MESH | apathy |
| disease | MESH | Amyotrophic lateral sclerosis |
| pathway | KEGG | Amyotrophic lateral sclerosis |
| disease | MESH | Gaucher disease |
| disease | MESH | neuroinflammation |